Clopidogrel bisulphate/Levamlodipine besylate

硫酸氢氯吡格雷/左旋苯磺酸氨氯地平

Report date: 2022/06/30 10:59:43

Base Information

Drug NameClopidogrel bisulphate/Levamlodipine besylate

Drug Alias NameS-amlodipine besylate/clopidogrel bisulphate硫酸氢氯吡格雷+左旋苯磺酸氨氯地平氯吡格雷/左旋氨氯地平Clopidogrel bisulphate+Levamlodipine besylateClopidogrel+levamlodipine +[11]

ClassificationSmall molecules

Mechanisms of ActionPlatelet aggregation inhibitorsPurinergic P2 receptor antagonistsVoltage-gated calcium channel blockers

TargetsVoltage-gated calcium channelPurinergic P2 receptor

Therapy Area/IndicationsHypertensionThrombosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesEmcure Pharma

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesEmcure Pharma

Active IndicationsN/A

Inactive IndicationsHypertensionThrombosis

Other Information

ATC CodeN/A